Pandelis, to say Mbila didn't turn out as expected is the understatement of the year, but it might be worth rechecking who was MD when Mbila was brought into the fold.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025